Trial
NCT00486759
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
Genentech, Inc.
Condition
B-cell Lymphoma
Intervention
Bevacizumab
Why stopped
Due to an unfavorable benefit/risk ratio.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-25